Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women

Wyeth is now a wholly owned subsidiary of Pfizer54 enrolled

Overview

The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Postmenopause

Interventions

PremarinDRUG

Eligibility

Sex: FEMALEMin age: 35 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Healthy postmenopausal women aged 35 to 70 years 2. Nonsmoker or smoker of less than 10 cigarettes per day Exclusion Criteria: 1. History or presence of clotting disorders 2. History or presence of cancer 3. Presence of HIV, hepatitis B or hepatitis C 4. History of drug or alcohol abuse

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.